Cybin (HELP) Shares Outstanding (Weighted Average) (2020 - 2025)
Cybin (HELP) reported Shares Outstanding (Weighted Average) of $16.2 million for Q2 2025, up 10.55% on a YoY basis from $14.6 million in Q2 2024, and up 7.35% quarter-over-quarter from $15.1 million in Q1 2025.
Cybin (HELP) Shares Outstanding (Weighted Average) (2020 - 2025) Analysis & Trends
Cybin has reported Shares Outstanding (Weighted Average) for 6 years, with the latest figure at $16.2 million in Q2 2025.
- For the quarter ending Q2 2025, Shares Outstanding (Weighted Average) rose 10.55% year-over-year to $16.2 million; the trailing twelve-month figure through Jun 2025 stood at $16.2 million (up 10.55% YoY), and the FY2025 full-year result was $15.5 million, down 95.28% from the prior year.
- Shares Outstanding (Weighted Average) for Q2 2025 stood at $16.2 million, up from $15.1 million in the prior quarter.
- The five-year high for Shares Outstanding (Weighted Average) was $4.6 billion in Q3 2023, with the low at $15.74 in Q2 2022.
- Historically, Shares Outstanding (Weighted Average) has averaged $367.4 million across 5 years, with a median of $124.4 million in 2021.
- The largest YoY upside for Shares Outstanding (Weighted Average) was 4820.87% in 2024 against a maximum downside of 99.68% in 2024.
- Cybin's Shares Outstanding (Weighted Average) stood at $110.7 million in 2021, then gained by 25.72% to $139.2 million in 2022, then sank by 95.36% to $6.4 million in 2023, then soared by 4820.87% to $317.4 million in 2024, then sank by 94.91% to $16.2 million in 2025.
- The last three Shares Outstanding (Weighted Average) figures came in at $16.2 million (Q2 2025), $15.1 million (Q1 2025), and $317.4 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 417.01 Bn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 928.40 Mn |
| 10 | Cybin | 75.42 Mn | 75.42 Mn | - | 16.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 16.17 Mn |
| Mar 31, 2025 | 15.06 Mn |
| Dec 31, 2024 | 317.40 Mn |
| Sep 30, 2024 | 14.66 Mn |
| Jun 30, 2024 | 14.62 Mn |
| Mar 31, 2024 | 329.41 Mn |
| Dec 31, 2023 | 6.45 Mn |
| Sep 30, 2023 | 4.60 Bn |
| Jun 30, 2023 | 153.47 Mn |
| Feb 28, 2023 | 51.91 |
| Dec 31, 2022 | 139.15 Mn |
| Sep 30, 2022 | 138.66 Mn |
| May 31, 2022 | 15.74 |
| Dec 31, 2021 | 110.68 Mn |
| Sep 30, 2021 | 131.70 Mn |
| Jun 30, 2021 | 128.30 Mn |
| Mar 31, 2021 | 124.40 Mn |
| Sep 30, 2020 | 51.89 Mn |
| Jun 30, 2020 | 43.78 Mn |